Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism

Journal of General Internal Medicine

Volumn 30, Issue 1, 2015, Pages 17-24

  Leiss, Waltraud ^a   Méan, Marie ^a   Limacher, Andreas ^b   Righini, Marc ^c   Jaeger, Kurt ^d   Beer, Hans Jürg ^e   Osterwalder, Joseph ^f   Frauchiger, Beat ^g   Matter, Christian M ^h   Kucher, Nils ^a   Angelillo Scherrer, Anne ^a   Cornuz, Jacques ⁱ   Banyai, Martin ^j   Lämmle, Bernhard ^a   Husmann, Marc ^h   Egloff, Michael ^e   Aschwanden, Markus ^d   Rodondi, Nicolas ^a   Aujesky, Drahomir ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Kantonsspital Baden   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g Kantonsspital Frauenfeld   (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

^j LUZERNER KANTONSSPITAL   (Switzerland)

more..

Author keywords

elderly; polypharmacy drugs; risk assessment; thromboembolism

Indexed keywords

ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANEMIA; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC THERAPY; GENDER; HUMAN; INCIDENCE; KIDNEY DISEASE; LIVER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; HEMORRHAGE; KAPLAN MEIER METHOD; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR; SWITZERLAND;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; POLYPHARMACY; PROSPECTIVE STUDIES; RISK FACTORS; SWITZERLAND; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84938981735     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2993-8     Document Type: Article

References (36)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the united states: The slone survey. JAMA. 2002;287:337–44.
2. Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna Region, Italy. Drugs Aging. 2010;27:1019–28.
3. Chen YF, Dewey ME, Avery AJ, the Analysis Group of the Medical Research Council Cognitive Function Ageing Study. Self-reported medication use for older people in England and Wales. J Clin Pharm Ther. 2001;26:129–40.
4. Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost. 2005;94:537–43.
5. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med. 1996;156:409–16.
6. Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004;164:2044–50.
7. Wehinger C, Stollberger C, Langer T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke. 2001;32:2246–52.
8. Donze J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125:773–8.
9. Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother. 2008;6:1–11.
10. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.
11. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952–60.
12. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant–antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35:2362–7.
13. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118:511–20.
14. Rosendaal FR, Van Hylckama VA, Doggen CJ. Venous thrombosis in the elderly. J Thromb Haemost. 2007;5:310–7.
15. Pengo V, Legnani C, Noventa F, Palareti G. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost. 2001;85:418–22.
16. Ageno W, Agnelli G, Imberti D, et al. Risk factors for venous thromboembolism in the elderly: results of the master registry. Blood Coagul Fibrinolysis. 2008;19:663–7.
17. Méan M, Aujesky D, Lämmle B, Gerschheimer C, Trelle S, Angelillo-Scherrer A. Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+). J Thromb Thrombolysis. 2013;36:484–91.
18. Méan M, Righini M, Jaeger K, et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis. 2013;36:475–83.
19. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA. 2007;297:77–86.
20. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.
21. Jakobsson C, Jimenez D, Gomez V, Zamarro C, Méan M, Aujesky D. Validation of a clinical algorithm to identify low-risk patients with pulmonary embolism. J Thromb Haemost. 2010;8:1242–7.
22. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–9.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
24. Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9:1460–7.
25. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390–6.
26. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91–9.
27. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31.
28. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.
29. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337–43.
30. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189–92.
31. Zarraga IG, Kron J. Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. J Am Geriatr Soc. 2013;61:143–50.
32. Ziere G, Dieleman JP, Hofman A, Pols HA, van der Cammen TJ, Stricker BH. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61:218–23.
33. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824–9.
34. Kämpfen P, Méan M, Limacher A, et al. Risk of falls and bleeding in elderly patients with acute venous thromboembolism. J Intern Med. 2014. doi:10.1111/joim.12236.
35. Casais P, Sanchez Luceros A, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol. 2000;63:192–6.
36. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15–20.